Aricept
(Donepezil)ApprovedSmall molecule
EisaiDonepezil is used to treat memory loss and thinking problems caused by Alzheimer's disease by helping to preserve a brain chemical that's important for memory and learning.[2] Aricept is currently approved and in use across 28 indications[4].[1]
Aricept is one of 551 small molecule programs targeting Memory Impairment. It is currently in Approved.
28
Indications
168
Total Trials
9
Active Trials
550
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 27 indications
Competition
Competitive Landscape
150 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Maridebart Cafraglutide
AmgenPhase 3
Retatrutide
Eli LillyPhase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
Elecoglipron
AstraZenecaPhase 3
GZR4
GGan and Lee Pharmaceuticals, USA
Phase 3
Imeglimin
PPoxel SA
Phase 3
HM11260C
Hanmi Pharmaceutical Company LimitedPhase 3
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease31 trials
Show 28 more trials
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2/3·NCT03090516·240 enrolled
Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease
Unknown status·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 2·NCT02305836·334 enrolled
Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease
Recruiting·—·N/A·NCT03810794·180 enrolled
Dementia14 trials
Show 11 more trials
Donepezil to Treat Dementia in Parkinson's Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 4·NCT00030979·28 enrolled
Donepezil Treatment of Psychotic Symptoms in Dementia Patients
Unknown status·—·Phase 3·NCT00190021·80 enrolled
Cognitive impairment10 trials
A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia
Unknown status·—·Phase 4·NCT01490567·80 enrolled
Show 7 more trials
Cognition8 trials
Show 5 more trials
Memory7 trials
Donepezil Memory Preservation Post ECT
Terminated·—·N/A·NCT02331771·12 enrolled
Show 4 more trials
Multicenter Evaluation of Memory Remediation After TBI With Donepezil
Completed·—·Phase 3·NCT02255799·75 enrolled
Donepezil Double Blind Trial for ECT Memory Disfunction
Unknown status·—·Phase 4·NCT00465283·40 enrolled
62 more indications
Mild to Moderate Alzheimer's Disease7 trials
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
Completed·—·Phase 4·NCT02787746·241 enrolled
Interaction5 trials
Stroke4 trials
Enhancing Rehabilitation After Stroke
Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00868010·200 enrolled
Parkinson's Disease4 trials
Delirium3 trials
Fed3 trials
Treatment3 trials
Aphasia2 trials
Fasting Conditions2 trials
Alzheimer disease2 trials
Cognitive Function2 trials
Fragile X Syndrome2 trials
Moderate to Severe Alzheimer's Disease2 trials
Tics2 trials
Amblyopia2 trials
Clinical Trial2 trials
Anorexia Nervosa2 trials
Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial
Not yet recruiting·—·Phase 2·NCT06687993·147 enrolled
Autism1 trial
HIE1 trial
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
Completed·—·Phase 3·NCT02550665·176 enrolled
Randomized1 trial
Metabolism1 trial
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
Recruiting·—·Phase 2·NCT06041789·45 enrolled
Urinary retention1 trial
Donepezil Prevents Urinary Retention After Extensive Total Hysterectomy
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT05540977·108 enrolled
Multiple Sclerosis1 trial
Neurodegenerative Disease1 trial
Aneurysm1 trial
Central Nervous System1 trial
Parkinson disease1 trial
Sleep1 trial
Adult1 trial
fMRI-behavioral Study of Cholinergic Augmentation With Donepezil in Healthy Sleep Deprived Adults
Completed·—·Phase 4·NCT00800553·43 enrolled
Smoking1 trial
Effect of Donepezil on Smoking
Completed·—·Phase 2·NCT01250977·30 enrolled
Cognitive Deficit1 trial
Orthopedic Surgery1 trial
Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period
Completed·—·Phase 2·NCT00586196·16 enrolled
Growth1 trial
Elderly Patients1 trial
Progressive Supranuclear Palsy1 trial
Schizophrenia1 trial
Irritation1 trial
Primary Brain Tumor1 trial
Peripheral Neuropathy1 trial
Diabetic Neuropathy1 trial
Women1 trial
Cognitive Functions1 trial
Rett syndrome1 trial
Study of the Pathogenesis of Rett Syndrome
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00004807·120 enrolled
Unspecified5 trials
Show 2 more trials
Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition
Completed·—·Phase 1·NCT01923558·76 enrolled
Regulatory
FDA Approval Timeline[5]
Nov 25, 1996
ARICEPT
NDA NDA020690
Oct 18, 2004
ARICEPT
NDA NDA021719
Oct 18, 2004
ARICEPT ODT
NDA NDA021720
Jul 23, 2010
ARICEPT
NDA NDA022568
Mar 11, 2022
ADLARITY
NDA NDA212304
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aricept drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Donepezil. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]